Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: Insights from the CAPITAIN and PREVAIL-US studies

Current Medical Research and Opinion

Volumn 30, Issue 5, 2014, Pages 775-784

  Chapman, M J ^a   Orsoni, A ^a   Robillard, P ^a   Hounslow, N ^b   Sponseller, C A ^c   Giral, P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Kowa Research Europe   (United Kingdom)

^c Kowa Pharmaceuticals America Inc   (United States)

Author keywords

Diabetogenicity; Dyslipidemia; Glucose homeostasis; Lipid profile; Metabolic syndrome; Statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG MEGADOSE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHASE 4 CLINICAL TRIAL (TOPIC); QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION STUDY;

BLOOD GLUCOSE; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRAVASTATIN; QUINOLINES; TRIGLYCERIDES;

EID: 84899092930     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.874989     Document Type: Article

References (32)

1. Rydé n L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
2. Genuth S, Eastman R, Kahn R, et al. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003;26:s28-32
3. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J 2011;32:1345-61
4. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 2012;19:585-667
5. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
6. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013;346:f2610
7. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30
8. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-64
9. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
10. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-7
11. FDA Drug Safety Communication: Important safety label changes to cholesterol- lowering statin drugs, 2012. Available at: Http://www.fda.gov/ drugs/drugsafety/ucm293101.htm#sa [Last accessed 15 May 2013]
12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
13. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome - A new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80
14. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012;380:565-71
15. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45
16. Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: A randomized controlled trial. Adv Ther 2011;28:811-23
17. Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther 2011;28:799-810
18. Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011;13:1047-55
19. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010;210:202-8
20. Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol 2013;20:29-39
21. Katz A, Nambi SS, Mather K, et al. Quantitative Insulin Sensitivity Check Index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10
22. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
23. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004;89:4963-71
24. Odawara M, Yamazaki T, Kishimoto J, et al. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. 49th EASD Annual Meeting, Barcelona, 23-27 September 2013
25. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
26. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control. Diabetologia 2006;49:1881-92
27. Boon J, Hoy AJ, Stark R, et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 2013;62:401-10
28. Drew BG, Rye KA, Duffy SJ, et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012;8:237-45
29. Miyamoto-Sasaki M, Yasuda T, Monguchi T, et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb 2013;20:708-16
30. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 2009;32:1924-9
31. Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol 2007;1:105-13
32. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-14.